---
figid: PMC5445606__41531_2016_1_Fig4_HTML
figlink: /pmc/articles/PMC5445606/figure/Fig4/
number: F4
caption: Insulin receptor signaling activates proteases for amyloidogenic proteins.
  A schematic figure showing that insulin receptor signaling pathway targets IDE and
  degrades both insulin and Aβ. Similarly, KLK6 may be regulated by insulin receptor
  signaling pathway to degrade αS
pmcid: PMC5445606
papertitle: Combined immunotherapy with “anti-insulin resistance” therapy as a novel
  therapeutic strategy against neurodegenerative diseases.
reftext: Yoshiki Takamatsu, et al. NPJ Parkinsons Dis. 2017;3:4.
pmc_ranked_result_index: '38613'
pathway_score: 0.9446884
filename: 41531_2016_1_Fig4_HTML.jpg
figtitle: Insulin receptor signaling activates proteases for amyloidogenic proteins
year: '2017'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5445606__41531_2016_1_Fig4_HTML.html
  '@type': Dataset
  description: Insulin receptor signaling activates proteases for amyloidogenic proteins.
    A schematic figure showing that insulin receptor signaling pathway targets IDE
    and degrades both insulin and Aβ. Similarly, KLK6 may be regulated by insulin
    receptor signaling pathway to degrade αS
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - KLK6
  - AKT1
  - AKT2
  - IDE
  - AKT3
genes:
- word: KLK6
  symbol: KLK6
  source: hgnc_symbol
  hgnc_symbol: KLK6
  entrez: '5653'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: IDE
  symbol: IDE
  source: hgnc_symbol
  hgnc_symbol: IDE
  entrez: '3416'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
chemicals: []
diseases: []
figid_alias: PMC5445606__F4
redirect_from: /figures/PMC5445606__F4
figtype: Figure
---
